{"mainPropery":{"diseaseId":6105,"diseaseName":"Chronic myeloid leukemia","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/6105/chronic-myeloid-leukemia","synonyms":["Chronic granulocytic leukemia","Chronic myelogenous leukemia","CML","Leukemia, chronic myeloid"],"synonyms-with-source":[{"name":"Chronic granulocytic leukemia"},{"name":"Chronic myelogenous leukemia"},{"name":"CML"},{"name":"Leukemia, chronic myeloid"}],"identifiers":[{"identifierType":"OMIM","identifierId":"608232"},{"identifierType":"ORPHANET","identifierId":"521"},{"identifierType":"UMLS","identifierId":"C0023473"}]},"diseaseCategories":[{"diseaseTypeId":12,"diseaseTypeName":"Blood Diseases","source":"Orphanet"},{"diseaseTypeId":1,"diseaseTypeName":"Rare Cancers"}],"organizations":[{"resourceID":426,"resourceName":"MPN Research Foundation","abbreviation":"","address1":"180 N. Michigan Avenue","address2":"Suite 1870","address3":"","address4":"","address5":"","city":"Chicago","state":"IL","zip":"60601","country":"United States","phone":"+1-312-683-7249","tty":"","tollFree":"+1-855-258-1943 (Support)","fax":"+1-312-332-0840 ","email":"rrosen@MPNResearchFoundation.org","url":"http://www.mpnresearchfoundation.org/","freeText":""},{"resourceID":4012,"resourceName":"National CML Society","abbreviation":"","address1":"130 Inverness Plaza #307","address2":"","address3":"","address4":"","address5":"","city":"Birmingham","state":"AL","zip":"35242","country":"United States","phone":"","tty":"","tollFree":"1-877-431-2573","fax":"","email":"info@nationalcmlsociety.org","url":"https://www.nationalcmlsociety.org/","freeText":""}],"resource descriptions":[{"id":7,"resourceId":10,"resourceName":"Online Mendelian Inheritance in Man (OMIM)","descriptionText":"<a href='http://www.omim.org/608232' target='_blank'>Online Mendelian Inheritance in Man (OMIM)</a> is a catalog of human genes and genetic disorders. Each entry has a summary of related medical articles. It is meant for health care professionals and researchers. OMIM is maintained by Johns Hopkins University School of Medicine.&nbsp;<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":8,"resourceId":11,"resourceName":"PubMed","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=omim&cmd=Display&dopt=omim_pubmed_calculated&from_uid=608232' target='_blank'>PubMed</a> is a searchable database of medical literature and lists journal articles that discuss Chronic myeloid leukemia. Click on the link to view a sample search on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":9,"resourceId":12,"resourceName":"ClinicalTrials.gov","descriptionText":"<a href='http://www.clinicaltrials.gov/ct2/results?cond=%22Chronic+myeloid+leukemia%22' target='_blank'>ClinicalTrials.gov</a> lists trials that are related to Chronic myeloid leukemia. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies. <br />\r\n<br />\r\n<em><strong>Please note:</strong>&nbsp;Studies listed on the&nbsp;ClinicalTrials.gov&nbsp;website are listed for informational purposes only; being listed does not reflect an endorsement by GARD or the NIH. We strongly recommend that you talk with a trusted healthcare provider before choosing to participate in any clinical study.</em>","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":10,"resourceId":13,"resourceName":"MedlinePlus Genetics","descriptionText":"<a href='https://ghr.nlm.nih.gov/condition/chronic-myeloid-leukemia' target='_blank'>Genetics Home Reference (GHR)</a> contains information on Chronic myeloid leukemia. This website is maintained by the National Library of Medicine.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":95,"resourceId":961,"resourceName":"SEER CML statistics","descriptionText":"<a href='http://seer.cancer.gov/statfacts/html/cmyl.html ' target='_blank'>SEER</a> provides information on cancer statistics. Click on the link to view statistical information on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":955,"resourceId":1652,"resourceName":"Myeloproliferative Disease Support and Daily Email Digest","descriptionText":"<a href='http://mpdsupport.org/ ' target='_blank'>MPD-Support</a>: Myeloproliferative Diseases Support and Daily E-mail Digest","resourceClassificationName":"Organizations","resourceClassificationSectionName":"Social Networking Websites"},{"id":981,"resourceId":1676,"resourceName":"MPN Education Foundation","descriptionText":"The <a href='http://www.mpnresearchfoundation.org/Essential-Thrombocythemia' target='_blank'>MPN Research Foundation</a> provides online information on myeloproliferative disorders (MPD). Click on the link to view the resource.","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":982,"resourceId":1677,"resourceName":"MPD-RC Myeloproliferative Disorders Research Consortium","descriptionText":"The&nbsp;<a href='https://mpdrc.org/home.php ' target='_blank'>Myeloproliferative Disorders Research Consortium (MPD-RC)</a> is an international, multi-institutional non-profit consortium funded by the National Cancer Institute (NCI) at the National Institutes of Health and set up to coordinate, facilitate, and perform basic and clinic research investigating the genetics of MPDs with the goal of developing therapy. To learn more, click on the link.","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":1457,"resourceId":2104,"resourceName":"Genetic Services","descriptionText":"To find a medical professional who specializes in genetics, you can ask your doctor for a referral or you can search for one yourself. Online directories are provided by the <a href='http://www.acmg.net/ACMG/Genetic_Services_Directory_Search.aspx' target='_blank'>American College of Medical Genetics</a> and the&nbsp;<a href='https://www.findageneticcounselor.com/' target='_blank'>National Society of Genetic Counselors</a>. If you need additional help, <a href=\"https://rarediseases.info.nih.gov/about-gard/contact-gard\">contact a GARD Information Specialist</a>. You can also&nbsp;<a href='https://ghr.nlm.nih.gov/primer#consult' target='_blank'>learn more about genetic consultations</a>&nbsp;from Genetics Home Reference.","resourceClassificationName":"Find a Specialist","resourceClassificationSectionName":"Healthcare Resources"},{"id":1526,"resourceId":2158,"resourceName":"Genetic Testing Registry","descriptionText":"The <a href='http://www.ncbi.nlm.nih.gov/gtr/conditions/C0023473' target='_blank'>Genetic Testing Registry</a> (GTR) provides information about the genetic tests for this condition. The intended audience for the GTR is health care providers and researchers. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.<br />\r\n","resourceClassificationName":"Diagnosis","resourceClassificationSectionName":"Testing Resources"},{"id":1527,"resourceId":2159,"resourceName":"National Organization for Rare Disorders","descriptionText":"The <a href='http://www.rarediseases.org/rare-disease-information/rare-diseases/byID/695/viewAbstract' target='_blank'>National Organization for Rare Disorders</a> (NORD) has a report for patients and families about this condition. NORD is a patient advocacy organization for individuals with rare diseases and the organizations that serve them.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1529,"resourceId":2128,"resourceName":"MedlinePlus","descriptionText":"<a href='http://www.nlm.nih.gov/medlineplus/ency/article/000570.htm' target='_blank'>MedlinePlus</a> was designed by the National Library of Medicine to help you research your health questions, and it provides more information about this topic.\r\n<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1531,"resourceId":2162,"resourceName":"Medscape Reference","descriptionText":"<a href='http://emedicine.medscape.com/article/199425-overview' target='_blank'>Medscape Reference</a> provides information on this topic. You may need to register to view the medical textbook, but registration is free.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1532,"resourceId":2163,"resourceName":"Social Security Administration","descriptionText":"The <a href='https://secure.ssa.gov/apps10/poms.nsf/lnx/0423022140' target='_blank'>Social Security Administration</a> has included this condition in their Compassionate Allowances Initiative. This initiative speeds up the processing of disability claims for applicants with certain medical conditions that cause severe disability. More information about <a href=\"http://www.ssa.gov/compassionateallowances/index.htm\" target=\"_blank\">Compassionate Allowances</a> and <a href=\"https://www.ssa.gov/benefits/disability/\" target=\"_blank\">applying for Social Security disability</a> is available online.","resourceClassificationName":"Living With","resourceClassificationSectionName":"Financial Resources"},{"id":1533,"resourceId":2164,"resourceName":"National Center for Biotechnology Information","descriptionText":"The <a href='http://www.ncbi.nlm.nih.gov/books/NBK22180/' target='_blank'>National Center for Biotechnology Information</a> (NCBI) was established in 1988 as a national resource for molecular biology information.  Click on the link to view information on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1534,"resourceId":2165,"resourceName":"Orphanet","descriptionText":"<a href='http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=521' target='_blank'>Orphanet</a> is a European reference portal for&nbsp;information on rare diseases and orphan drugs. Access to this database is free of charge.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1543,"resourceId":2171,"resourceName":"National Cancer Institute","descriptionText":"The <a href='http://www.cancer.gov/cancertopics/pdq/treatment/CML/HealthProfessional/page2' target='_blank'>National Cancer Institute</a> provides the most current information on cancer for patients, health professionals, and the general public.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/OMIM:608232' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":2160,"resourceId":3368,"resourceName":"Patient Access Network Foundation","descriptionText":"<a href='https://panfoundation.org/index.php/en/patients/assistance-programs/myelodysplastic-syndromes' target='_blank'>Patient Access Network Foundation</a> (PAN Foundation) has Assistance Programs for those with health insurance who reside in the United States. The disease fund status can change over time, so you may need to check back if funds are not currently available.&nbsp;","resourceClassificationName":"Living With","resourceClassificationSectionName":"Financial Resources"},{"id":2163,"resourceId":3372,"resourceName":"Good Days","descriptionText":"<a href='https://www.mygooddays.org/patients/diseases-covered/chronic-iron-overload' target='_blank'>Good Days</a> provides help to patients with life-altering conditions. Assistance includes help with the cost of medications and travel.","resourceClassificationName":"Living With","resourceClassificationSectionName":"Financial Resources"}],"overviewQuestion":{"questionId":0,"dateModified":"0001-01-01T00:00:00"},"basicQuestions":[],"references":[],"relatedDiseases":[{"relatedDiseaseId":9319,"relatedDiseaseName":"Chronic myeloproliferative disorders","relation":"Parent","isRare":true,"hasGardPage":true},{"relatedDiseaseId":8226,"relatedDiseaseName":"Myeloid leukemia","relation":"Parent","isRare":true,"hasGardPage":true}],"gardCases":[],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[{"phenoTypeId":9580,"phenoTypeName":"Myeloproliferative disorder","frequencyText":"Obligate","percentRanges":"100%"},{"phenoTypeId":15547,"phenoTypeName":"Abnormal basophil morphology","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":13704,"phenoTypeName":"Fatigue","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":13043,"phenoTypeName":"Fever","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":13075,"phenoTypeName":"Leukocytosis","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":10361,"phenoTypeName":"Poor appetite","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":3886,"phenoTypeName":"Splenomegaly","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":15512,"phenoTypeName":"Thrombocytopenia","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":15530,"phenoTypeName":"Thrombocytosis","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":9542,"phenoTypeName":"Chronic myelogenous leukemia","percentRanges":"-"},{"phenoTypeId":10836,"phenoTypeName":"Ph-positive acute lymphoblastic leukemia","percentRanges":"-"},{"phenoTypeId":10842,"phenoTypeName":"Reduced leukocyte alkaline phosphatase","percentRanges":"-"},{"phenoTypeId":8123,"phenoTypeName":"Somatic mutation","percentRanges":"-"}],"medicalProducts":[{"productId":549,"genericName":"Bosutinib","tradeName":"Bosulif","tradeLink":"http://www.bosulif.com","manufacturer":"","sponsor":"Pfizer Inc.","indication":"Treatment of adult patients with newly-diagnosed chronic phase Philadelphia chromosome-positive chronic myelougenous leukemia. Also for treatment of adult patients with chronic, accelerated or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance, or intolerance to prior therapy.","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/rn/380843-75-4","medlinePlusLink":"https://medlineplus.gov/druginfo/meds/a613005.html"},{"productId":509,"genericName":"Imatinib mesylate","tradeName":"Gleevec®","tradeLink":"http://www.gleevec.com/index.jsp?usertrack.filter_applied=true&NovaId=1178761786655757289","manufacturer":"","sponsor":"Novartis Pharmaceuticals Corp.","indication":"Treatment of chronic myelogenous leukemia","drugInformationLink":"http://druginfo.nlm.nih.gov/drugportal/dpdirect.jsp?name=Gleevec","medlinePlusLink":""},{"productId":563,"genericName":"Ponatinib","tradeName":"Iclusig","tradeLink":"http://www.ariad.com/wt/page/ICLUSIG","manufacturer":"ARIAD Pharmaceuticals Inc.","sponsor":"ARIAD Pharmaceuticals Inc.","indication":"Treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy.  ","drugInformationLink":"http://druginfo.nlm.nih.gov/drugportal/dpdirect.jsp?name= Iclusig","medlinePlusLink":""},{"productId":250,"genericName":"Interferon alfa-2a (recombinant)","tradeName":"Roferon®-A","tradeLink":"http://www.rocheusa.com/products/roferon/","manufacturer":"","sponsor":"Hoffmann-La Roche, Inc.","indication":"Treatment of chronic myelogenous leukemia.","drugInformationLink":"http://druginfo.nlm.nih.gov/drugportal/dpdirect.jsp?name=Roferon+A","medlinePlusLink":""},{"productId":76,"genericName":"Dasatinib","tradeName":"Sprycel","tradeLink":"https://www.sprycel.com/","manufacturer":"","sponsor":"Bristol-Myers Squibb Company","indication":"December 2018, dasatinib (Sprycel) was approved for the treatment of pediatric patients 1 year of age and older with Ph+ CML in chronic phase and newly diagnosed Ph+ ALL in combination with chemotherapy. Previously in June 2013, it was approved for treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy.","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/rn/863127-77-9","medlinePlusLink":"https://medlineplus.gov/druginfo/meds/a607063.html"},{"productId":555,"genericName":"Omacetaxine mepesuccinate","tradeName":"Synribo","tradeLink":"http://www.tevapharm.com/Media/News/Pages/2012/1750668.aspx","manufacturer":"","sponsor":"Teva Pharmaceuticals","indication":"Treatment of chronic myelogenous leukemia","drugInformationLink":"http://druginfo.nlm.nih.gov/drugportal/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=drugportal&actionHandle=default&nextPage=jsp/drugportal/ResultScreen.jsp&TXTSUPERLISTID=0026833874&QV1=SYNRIBO","medlinePlusLink":""},{"productId":350,"genericName":"Nilotinib","tradeName":"Tasigna","tradeLink":"https://www.us.tasigna.com/","manufacturer":"","sponsor":"Novartis Pharmaceutical Corporation","indication":"March 2018 approved for the treatment of pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase and pediatric patients greater than or equal to 1 year of age with chronic phase Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) with resistance or intolerance to prior tyrosine-kinase inhibitor (TKI) therapy. \r\n\r\nOctober 2014 approved for treatment of chronic phase (CP) and accelerated phase (AP) Philadelphia chromosome positive chronic myelogenous leukemia  (CML) in adult patients resistant to or intolerant to prior therapy that included Gleevec(imatinib)","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/rn/641571-10-0","medlinePlusLink":"https://medlineplus.gov/druginfo/meds/a608002.html"}],"EncodedName":"Chronic_myeloid_leukemia"}